GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer’s disease may not be among them.
CytomX reports ADC data in late-line colorectal cancer; FDA OKs Cosentyx label expansion
Plus, news about Bayer’s Kerendia, Eli Lilly’s Ebglyss and Alto Neuroscience: 📈 CytomX’s colorectal cancer data: The biotech tested multiple doses of its antibody-drug conjugate


